Published On: 8/27/2024
ISPE 2024 Research: Presentation by Kathleen Hurwitz ScD, Catherine Wiener, and Chase Latour
Team members Kathleen Hurwtiz, ScD, Catherine Wiener, and Chase Latour helped author a new Target RWE study presented at ISPE 2024 titled “Comparing causal estimands from a sequential nested trial emulation with a treatment decision design to a conventional single point randomized trial: A simulation study.”
The study investigates the potential biases in sequential nested trial emulations, a study designed for rare disease research. Using a simulation framework, the authors compared the results of sequential nested trial emulation to those of single-point randomized trials. Watch this research presentation for valuable insights on using sequential nested trial emulations, highlighting the importance of careful study design and analysis to ensure accurate results:
About Target RWE
Target RWE generates real-world evidence (RWE) that informs strategic decisions across the drug development lifecycle. Our unique combination of clinical, analytical and technical expertise enables comprehensive insight generation from complete retrospective and prospective longitudinal patient journeys, with unparalleled scale and accuracy.
Visit our website to learn more: https://targetrwe.com/
Contact:
Kayla Slake
Senior Manager, Marketing
984.234.0268 ext 205
More News
-
03/31/2025
Addressing the Burden of Hidradenitis Suppurativa: The Often-Hidden Impact on Quality of Life -
03/18/2025
AASLD Opens Call for Applications for Sites to Participate in TARGET-LD and the Cirrhosis Quality Collaborative (CQC Data Registry) -
03/07/2025
Patient-Centric Data Capture Fuels Growth of Target RWE Longitudinal, Real-World Dermatology Studies -
02/20/2025
Causal Inference for Regulatory-Grade Evidence Generation: Behind the Data -
01/31/2025
Maximizing the Value of Real-World Data: The Critical Role of Causal Inference in Pharmaceutical Innovation